News & Updates
Filter by Specialty:
Once-weekly semaglutide safe, effective in type 2 diabetes patients
Initiating a once-weekly treatment regimen of semaglutide helps control glycated haemoglobin (HbA1c) levels and body weight in patients with type 2 diabetes, without introducing new safety concerns, a Japan study has found.
Once-weekly semaglutide safe, effective in type 2 diabetes patients
13 Nov 2022
Immune response to flu shots preserved in seniors with well-controlled metabolic comorbidities
Older adults with well-controlled metabolic comorbidities exhibit immune response to influenza vaccine, as shown in the results of the DYNAMIC study. Notably, physical activity further increases immune response particularly for influenza A/H3N2.
Immune response to flu shots preserved in seniors with well-controlled metabolic comorbidities
11 Nov 2022
Prasugrel on par with clopidogrel in reducing stroke recurrence in thrombotic stroke patients
In thrombotic stroke patients at high risk of ischaemic stroke recurrence, prasugrel was as effective as clopidogrel in reducing the composite incidence of ischaemic stroke, MI, and death from other vascular causes, the phase III PRASTRO-III study has shown.
Prasugrel on par with clopidogrel in reducing stroke recurrence in thrombotic stroke patients
11 Nov 2022
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
AF does not reduce dapagliflozin efficacy in HF patients
The presence of atrial fibrillation (AF) at baseline does not appear to modify the benefits of dapagliflozin, compared with placebo, on symptoms and clinical events in patients with heart failure and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), according to a study.
